Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment

Hanna Fredholm, Sonja Eaker, Jan Frisell et al. · 2009

Read Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment by Hanna Fredholm, Sonja Eaker, Jan Frisell et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007695.txt.

Introduction

Hanna Fredholm and co-authors published a study in PLOS ONE in 2009. It concerns breast cancer in young women. The disease is uncommon before middle age, yet it is the most frequent cancer in women under forty. Young patients also tend to fare worse than older ones.

The team measured survival in young women and asked how much of the gap strong treatment could close. Their answer, summed in the title, is sobering. Even with intensive treatment, young women died at higher rates. The study makes the case for research aimed at the distinct biology of early breast cancer.

Catalog record

CREATORHanna Fredholm, Sonja Eaker, Jan Frisell et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007695

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment Authors: Hanna Fredholm, Sonja Eaker, Jan Frisell, Lars Holmberg, Irma Fredriksson, Henrik Lindman Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0007695 ABSTRACT Breast cancer is uncommon in young women and correlates with a less favourable prognosis; still it is the most frequent cancer in women under 40, accounting for 30–40% of all incident female cancer. The aim of this study was to study prognosis in young women, quantifying how much stage at diagnosis and management on the one hand, and tumour biology on the other; each contribute to the worse prognosis seen in this age group. In a registry based cohort of women aged 20–69 (n = 22 017) with a primary diagnosis of invasive breast cancer (1992–2005), women aged 20–34 (n = 471), 35–39 (n = 858) and 40–49 (n = 4789) were compared with women aged 50–69 years (n = 15 899). The cumulative 5-year relative survival ratio and the relative excess mortality (RER) were calculated. The cumulative 5-year relative survival ratio was lowest in women aged 20–34. The RER was 2.84 for women aged 20–34 and decreased with increasing age (RER 1.76 and 1.17 for women aged 35–39 and 40–49, respectively). The excess risk was, however, present only in disease stages I and II. For women aged 20–34 with stage I disease RER was 4.63, and 6.70 in the subgroup with tumour size 1–10 mm. The absolute difference in stage I between the youngest and the reference groups amounted to nearly 8%, with a 90% 5-year survival in women aged 20–34. In stages IIa and IIb, the relative excess risk was not as dramatic, but the absolute differences approached 15%. The youngest women with small tumours generally received more aggressive treatment than women in older age groups. After correction for stage, tumour characteristics and treatment, age remained an independent risk factor for breast cancer death in women <35 years of age. The excess risk for young women was only seen in early stages of disease and was most pronounced in women with small tumours. Young women affected by breast cancer have a high risk of dying compared to their middle-aged counterparts even if diagnosed early and receiving an intense treatment. INTRODUCTION Approximately 7% of all breast cancers are diagnosed in women <40 years of age and less than 4% in women below the age of 35 [1] , [2] , [3] . Although breast cancer is uncommon in young women, it is the most frequent cancer in women <40, accounting for 30–40% of all incident female cancer [4] , [5] . Young age at diagnosis influences prognosis negatively [1] , [6] , [7] , [8] , [9] , [10] . This could partly be explained by young women more often being diagnosed at advanced stages [1] , [11] and by unfavourable tumour characteristics more often being present [8] , [11] , [12] , [13] , [14] , [15] . It has not been quantified how much stage at diagnosis and management on one hand, and tumour biology on the other, each contribute to the poor prognosis. At the other end of the age spectrum, breast cancer in elderly women is also associated with an inferior prognosis when compared to that of middle-aged women [6] , [16] . In a prior study we focused on the elderly and found that less diagnostic activity and less intensive treatment were major explanations for their relatively low survival [17] . We interpreted our findings to be partly due to less rigorous guidelines for the treatment of women aged >70 and were alarmed that unclear guidelines might also contribute to the worse prognosis seen in young women, since guidelines for treating younger women have been less structured than for middle-aged women. The aim of the present study was to investigate to what degree a worse prognosis in young women can be explained by stage, tumour characteristics and treatment procedures. METHODS Data were collected from the regional breast cancer registers in two of Sweden's six health-care regions (Stockholm/Gotland and Uppsala/Örebro), which currently serve a population of almost 3.9 million inhabitants, thus covering about 43% of the Swedish population. The registers contain prospectively collected data on patient and tumour characteristics, types of treatment and follow-up. The registers are updated continuously by matching with the National Population Register and the mandatory Swedish Cancer Register to ensure a high coverage. The validity of the Swedish Cancer Register has been tested previously and found to be very high for the purpose of breast cancer studies [18] , [19] . A cohort of all women aged 20–69 with a primary diagnosis of invasive breast cancer between 1992 and 2005 was followed until the end of 2006. Of the original cohort, 22 017 women were eligible after exclusion of 52 women with less than one month follow-up. Women with bilateral disease at diagnosis were included only once, with the most advanced cancer as the index tumour. For women offered neoadjuvant treatment and those not operated on, staging was based on clinical and preoperative biopsy data. Data on tumour stage were based on the UICC criteria for histopathological TNM stage [20] . The age interval was chosen to allow comparison of young women with middle-aged women, as the latter group is known to have the best survival [10] , [21] , [22] , [23] . The time interval was chosen to represent recent clinical practice and registration procedures, i.e. with homogeneous treatment guidelines and full coverage by regional breast cancer registers. We chose the cut off at 50 years to define young women and further divided them into three groups (20–34 years, 35–39 years and 40–49 years) in accordance with earlier studies and current treatment recommendations for women <35 years [24] . Women aged 50–69 years served as a comparison group. All women aged 50–69 years were invited to screening mammography every second year. For women aged 40–49 the routines for screening mammography differed between the two regions, implying that approximately 50% of women aged 40–49 were invited for mammography with an interval of 1.5 years, while the other 50% were not. 2.2. TREATMENT During the study period treatment for breast cancer was performed according to regional and national guidelines that closely follow international practice. Surgery involved either modified radical mastectomy or breast conserving surgery [25] , combined with either a level I and II axillary clearance [26] or a sentinel node biopsy [27] . Radiotherapy to the remaining breast parenchyma up to a total dose of 50–54 Gy (Grey) was recommended as standard treatment after breast conserving surgery. Since 2003 a boost of 10–16 Gy to the tumour bed has been offered to women of 40–45 years. Radiotherapy to the axilla in a dose of 46–54 Gy has been given to women with involved axillary nodes (to all with ≥4 involved nodes and to a majority with 1–3 involved nodes). After mastectomy a total dose of 50–54 Gy has been given to the chest wall if the tumour primarily invaded the pectoral muscle, if extensive multifocality, when tumour size ≥50 mm or smaller if involved axillary nodes. During the early years of the study period, tamoxifen was not routinely given to

Read the complete text